Evaxion Biotech A/S Receivables

The latest receivables for EVAX is $1.9M as of June 2026. That compares with $860K in the prior-year period — up 115.0% year over year. Investors often review this figure alongside Evaxion Biotech A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, EVAX's receivables moved from $860K to $1.9M — a 115.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Evaxion Biotech A/S's operating scale or balance-sheet position.

A receivables figure of $1.9M for EVAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EVAX's receivables ($1.9M), review year-over-year change from $860K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Evaxion Biotech A/S's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.